Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6064659 | 1.00 | CETP (0.43) | CETPAOC3 | |
| SCHEMBL5668400 | 0.95 | CETP (0.40) | CETPAOC3 | |
| SCHEMBL6274573 | 0.95 | CETP (0.40) | CETPAOC3 | |
| SCHEMBL6229027 | 0.94 | CETP (0.42) | CETPAOC3 | |
| SCHEMBL6431631 | 0.94 | CETP (0.42) | CETPAOC3 | |
| SCHEMBL6568898 | 0.92 | CETP (0.44) | CETP | |
| SCHEMBL5670800 | 0.92 | CETP (0.44) | CETP | |
| SCHEMBL5670346 | 0.92 | CETP (0.41) | CETPAOC3 | |
| SCHEMBL6568915 | 0.92 | CETP (0.41) | CETPAOC3 | |
| SCHEMBL6823366 | 0.90 | CETP (0.43) | CETPAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1653926-A1 | DOSAGE FORMS PROVIDING CONTROLLED RELEASE OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND IMMEDIATE RELEASE OF HMG-COA REDUCTASE INHIBITORS | Pfizer Products Inc. (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1519754-A1 | USE OF CETP INHIBITORS AND OPTIONALLY HMG COA REDUCTASE INHIBITORS AND/OR ANTIHYPERTENSIVE AGENTS | Pfizer Products Inc. (US) | 2005-04-06 | — | — | EP | disclosed |
| EP-1519752-A1 | USE OF CETP INHIBITORS AND ANTIHYPERTENSIVE AGENTS AS WELL AS OPTIONALLY HMG COA REDUCTASE INHIBITORS | Pfizer Products Inc. (US) | 2005-04-06 | — | — | EP | disclosed |
| WO-2005011634-A1 | DOSAGE FORMS PROVIDING CONTROLLED RELEASE OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND IMMEDIATE RELEASE OF HMG-COA REDUCTASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| EP-1404300-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUGS AND NEUTRAL POLYMERS | Pfizer Products Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| EP-1401503-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A SOLID DISPERSION OF A POORLY-SOLUBLE DRUG IN A MATRIX AND A SOLUBILITY-ENHANCING POLYMER | Pfizer Products Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| EP-1399190-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING LOW-SOLUBILITY AND/OR ACID-SENSITIVE DRUGS AND NEUTRALIZED ACIDIC POLYMERS | Pfizer Products Inc. (US) | 2004-03-24 | — | — | EP | disclosed |
| WO-2004004777-A1 | USE OF CETP INHIBITORS AND ANTIHYPERTENSIVE AGENTS AS WELL AS OPTIONALLY HMG COA REDUCTASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| WO-2004004778-A1 | USE OF CETP INHIBITORS AND OPTIONALLY HMG COA REDUCTABLE INHIBITORS AND/OR ANTIHYPERTENSIVE AGENTS | PFIZER PRODUCTS INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| WO-2003000235-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUGS AND NEUTRAL POLYMERS | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000292-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING LOW-SOLUBILITY AND/OR ACID-SENSITIVE DRUGS AND NEUTRALIZED ACIDIC POLYMERS | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000294-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A SOLID DISPERSION OF A POORLY-SOLUBLE DRUG IN A MATRIX AND A SOLUBILITY-ENHANCING POLYMER | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |